Skymark Research Initiates Independent Research Coverage On Hythiam, Inc.

Skymark Research Initiates Independent Research Coverage On Hythiam, Inc. - Yahoo! Finance.gnwlistitemmarginbottom {margin-bottom: 10.0px} .gnwtablebottommargin {margin-bottom: 10.0px} .gnwcellpaddingleft0 {padding-left: 0.0px} .gnwverticalaligntop {vertical-align: top} .gnwtextaligncenter {text-align: center} .gnwcellparagraphmargin {margin-bottom: 0px; margin-top: 0px} .gnwverticalalignbottom {vertical-align: bottom} .gnwwhitespacenowrap {white-space: nowrap} .gnwtextalignright {text-align: right} .gnwcellpaddingright0 {padding-right: 0.0px} .gnwunderlinestyle {text-decoration: underline} .gnwtextalignleft {text-align: left} .gnw_heading {font: 16px Arial; text-align: center} .gnw_subhead {font: 12px Arial; text-align: center} .gnw_colhead {font: 12px Arial; text-align: center} .gnw_colhead_uline {font: 12px Arial; text-align: center; border-bottom: solid black 1.0pt;} .gnw_colhead_dline {font: 12px Arial; text-align: center; border-bottom: double black 2.5pt;} .gnw_label {font: 12px Arial; vertical-align: bottom; text-align: left } .gnw_label_uline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: solid black 1.0pt;} .gnw_label_uline_i10 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i15 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i20 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i25 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i30 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_dline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: double black 2.5pt;} .gnw_label_i10 {font: 12px Arial; vertical-align: bottom; text-align: left; padding-left: 10.0px;} .gnw_label_i15 {font: 12px Arial; vertical-align: bottom; text-align: left;...
Click here to read the whole Article (external link)

Hythiam Receives NASDAQ Notification Regarding Bid Price; Grace Period Granted Through March 15, 2010

LOS ANGELES--(BUSINESS WIRE)--Hythiam, Inc. (NASDAQ:HYTM - News) announced today that on September 15, 2009, the Company received a letter from The NASDAQ Stock Market indicating that because the bid price of the Company’s common stock had closed below the minimum $1.00 per share threshold as set forth in NASDAQ Listing Rule 5450(a)(1) for the prior 30 consecutive business days, the Company has been provided 180 calendar days, or until March 15, 2010, to regain compliance with the minimum bid price requirement. The most recent notice does not impact the Company’s listing on NASDAQ at this time. If at any time during this grace period the bid price of the Company’s security closes at $1.00 per share or more for a minimum of ten consecutive business days, the Company will regain compliance with the minimum bid price requirement. About Hythiam®TM® Treatment Program for alcoholism and stimulant dependence. The PROMETA Treatment Program, which integrates behavioral, nutritional, and medical components, is also available on a private-pay basis through licensed treatment providers and company managed treatment centers. Hythiam, Inc. does not practice medicine or manufacture, distribute, or sell any medications and has no relationship with any manufacturers or distributo...
Click here to read the whole Article (external link)

Hythiam Announces the Closing of $7 Million Registered Direct Offering

LOS ANGELES--(BUSINESS WIRE)--Hythiam, Inc. (NASDAQ:HYTM - News) announced today that on Tuesday, September 22, 2009 it closed the previously announced registered direct placement of 9,333,334 shares of its common stock to institutional investors at a price per share of $.75 for gross proceeds of $7 million. Investors also received warrants to purchase 2,333,334 shares of the Company’s common stock. The warrants have an exercise price of $.85 per share and are exercisable at any time after the closing of the transaction and before the 3rd anniversary of such initial issuance date. The shares and warrants were offered by the Company pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission dated and declared effective on September 11, 2009.This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The shares of common stock and warrants may only be offered by means of a prospectus. Copies of the final prospectus supplement and accompanying base prospectus can be obtained from the SEC's website at ...
Click here to read the whole Article (external link)

HYTHIAM INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Trans

Show all filings for HYTHIAM INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for HYTHIAM INC 21-Sep-2009Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Trans Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" ...
Click here to read the whole Article (external link)

Hythiam Announces First Peer-Reviewed Publication of Statistically Significant Results from Randomized, Double-Blind, Placebo-Controlled Study

LOS ANGELES--(BUSINESS WIRE)--Hythiam, Inc. (NASDAQ:HYTM - News)®Journal of Clinical Psychopharmacology,Journal of Clinical Psychopharmacology, Volume 29, Number 4, August 2009, pp. 334-342. The study was conducted at the Medical University of South Carolina, and among the researchers’ findings were that key results demonstrated a statistically significant difference in use for subjects who exhibited pre-treatment withdrawal symptoms. The results are the first to be published in a peer-reviewed scientific journal from a double-blind, placebo-controlled study conducted to assess the impact of the PROMETA Treatment Program on alcohol dependence. “We are pleased that results from the double-blind, placebo-controlled studies are beginning to publish in academic journals,” said Hythiam’s Senior Vice President of Scientific Affairs, Dr. Gary Ingenito. “Peer-review publication brings additional validation to the PROMETA Treatment Program, and results from the alcohol studies are providing greater clarity for clinicians as to when use of the PROMETA Treatment Program in alcohol dependent patients may be beneficial. We look forward to several publications of results from other completed double-blind studies in peer-reviewed journals, and expect those results to help create a more complete picture regarding the impact of the PROMETA Treatment Program on sub...
Click here to read the whole Article (external link)

Pocket Rockets: 3 Promising PowerRatings Stocks Under $3

David Goodboy is Vice President of Business Development for a New York City based multi-strategy fund. The stock market is setting up for its 2nd straight winning day on Tuesday. Momentum from Monday's rally and world stock markets turning higher appear to be powering U.S. stocks today.In a solid sign of confidence, Australia has become the first economy to raise interest rates. Despite the positive economic signals, no one really knows what will happen to the market or even individual stocks over the next week.Some stocks will win others will lose this week. Short-term traders need proven tools to choose stocks most likely to appreciate over the next 5 days. Our Stock PowerRatings are one such dynamic tool. 14 years of extensive, statistically valid studies have proven our Stock PowerRatings to be exactly what short-term traders need to evaluate and choose stocks to buy for the short-term.The proprietary calculating engine behind the PowerRatings is constantly scanning the universe of stocks ranking them in a 1 to 10 rating system. Our studies have clearly proven that stocks with a 10 Stock PowerRatings outperform the average stock by a 14.7 to 1 margin. 4, 5, 6, 7 rated stocks have proven to simply perform with the market. The low rated 1, 2 and 3 ranked stocks have proven to simply be too volatile thus risky for short term appreciation.One of the coolest things about Stock PowerRatings is the screeners available. Here are 3 stocks from the screener that locates highly rated, low priced companies poised for potential short-term gains.Hythiam (NasdaqGM:HYTM - ...
Click here to read the whole Article (external link)

Hythiam Partners With Relapse Prevention Specialist, Dr. Alan Marlatt to Develop the OnTrak(TM) Psychosocial Program for Substance Dependence

LOS ANGELES, Oct. 8, 2009 (GLOBE NEWSWIRE) -- Hythiam, Inc. (Nasdaq:HYTM - News) announced today that the Company partnered with Dr. Alan Marlatt to develop the OnTrak Relapse Prevention Program (ORPP), a proprietary, outpatient, evidence-based psychosocial program that is a key component of the Catasys integrated substance dependence offering. Dr. Marlatt is a professor of psychology at the University of Washington in Seattle, and a renowned researcher in the field of relapse prevention alcohol studies and addiction. He has published numerous books and articles on alcoholism, relapse prevention and addiction, and has received multiple awards recognizing his contributions to research and knowledge in the field of relapse prevention alcohol studies and addiction. Dr. Marlatt worked closely with the Company to develop ORPP, an outpatient program with a focus on integration of medical and care coaching components, standardization, and the reduction of practice pattern variation. "I was pleased to work with Hythiam to broaden their evidence-based psychosocial program focused on relapse prevention, understanding that it would be integrated as part of a larger program dedicated to treating substance dependence," said Dr. Marlatt. "Their focus on integration and standardization, and their approach to combining medical intervention with psychosocial and care coaching components into a single program dedicated to helping substance dependent individuals achieve and maintain recovery is consistent with the latest scientific development...
Click here to read the whole Article (external link)

Hythiam Announces Third Quarter Results

Hythiam, Inc. and Subsidiaries Consolidated Statements of Operations (unaudited)             Three Months Ended Nine Months Ended (in thousands, except per share data) September 30, September 30,   2009     2008     2009     2008   Revenues Healthcare services $ 268   $ ...
Click here to read the whole Article (external link)

HYTHIAM INC Financials

Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...
Click here to read the whole Article (external link)

HYTHIAM INC Files SEC form 8-K, Results of Operations and Financial Condition

Show all filings for HYTHIAM INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for HYTHIAM INC 9-Nov-2009Results of Operations and Financial Condition Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not inten...
Click here to read the whole Article (external link)